Furthermore, since increased glycolysis leads to chemoresistance in breast cancer, determining the LDH-B/LDH-A ratio, would suggest a rationale that either NF-kB or LDH-A inhibitors could be added to current treatment regimens. This evidence concerns the gene LDHA and breast cancer.